Vice President Clinical Pharmacology
John A. Oates MD

Dr. Oates is a major contributor to the current understanding of the mechanism by which acetaminophen inhibits the cyclooxygenases and how this accounts for the cellular selectivity of the drug.  His more recent work led to the discovery that acetaminophen is an inhibitor of hemeprotein-catalyzed lipid peroxidation with a potency sufficient to inhibit this process in vivo.  Based on these discoveries, he and Ned Porter have developed a series of inhibitors of hemoprotein-catalyzed lipid peroxidation with the aim of achieving efficacy without hepatotoxicity.

Positions and Honors
Employment

1956 - 1957 Internship (Internal Medicine), New York Hospital, Cornell Medical Center, New York
1957-1958 Resident (Cardiology), New York Hospital, Cornell Medical Center, New York, New York
1958-1961 Clinical Associate, National Heart Institute, Bethesda, Maryland
1961-1962 Resident (Internal Medicine), New York Hospital, Cornell Medical Center, New York
1962 - 1963 Senior Investigator, National Heart Institute, Bethesda, Maryland
1963 - 1965 Assistant Professor of Medicine and Pharmacology, Vanderbilt University, Nashville, TN
1963 - 1988 Director, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee
1965 - 1969 Associate Professor, Vanderbilt University, Nashville, Tennessee
1967 - 2001 P.I., NIGMS Research Center for Clinical Pharmacology and Drug Toxicology
1969-Present  Professor of Medicine and Pharmacology
1983 - 1997 Chairman, Department of Medicine, Vanderbilt University, Nashville, Tennessee
2007 - 2010 P.I., NIGMS Research Center for Clinical Pharmacology and Drug Toxicology

2008 - 2011

P.I., SCCOR in Hemostatic and Thrombotic Diseases, NHLBI

2014 - present 

VDDI Pharmaceuticals, Vice President of Clinical Pharmacology
2014 - present    Member, Scientific Advisory Board and Consultant VDDI Pharmaceuticals


        

go back go next